The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model

References

• Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604–615; PMID:15100338; http://dx.doi.org/10.1093/jnci/djh104
   PubMed Web of Science ®Google Scholar
• Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9:37–48; PMID:12533280; http://dx.doi.org/10.3201/eid0901.020168
   PubMed Web of Science ®Google Scholar
• Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290:781–9; PMID:12915431; http://dx.doi.org/10.1001/jama.290.6.781
   PubMed Web of Science ®Google Scholar
• Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10:1915–23; PMID:15550200; http://dx.doi.org/10.3201/eid1011.040222
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13:28–41; PMID:17370513; http://dx.doi.org/10.3201/eid1301.060438
   PubMed Web of Science ®Google Scholar
• Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008; 14:244–51; PMID:18258117; http://dx.doi.org/10.3201/eid1402.070499
   PubMed Web of Science ®Google Scholar
• Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359:821–32; PMID:18716299; http://dx.doi.org/10.1056/NEJMsa0707052
   PubMed Web of Science ®Google Scholar
• Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009; 339:b3884; PMID:19815582; http://dx.doi.org/10.1136/bmj.b3884
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010; 28:6858–67; PMID:20713101; http://dx.doi.org/10.1016/j.vaccine.2010.08.030
   PubMed Web of Science ®Google Scholar
• Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011; 29:8443–50; PMID:21816193; http://dx.doi.org/10.1016/j.vaccine.2011.07.096
   PubMed Web of Science ®Google Scholar
• Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003–2010: Potential impact of HPV vaccination. Am J Public Health 2013; 103:1428–35; PMID:23763409; http://dx.doi.org/10.2105/AJPH.2012.301182
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, Unger ER. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis 2013; 208:385–93; PMID:23785124; http://dx.doi.org/10.1093/infdis/jit192
   PubMed Web of Science ®Google Scholar
• Hariri S, Markowitz LE, Dunne EF, Unger ER. Population impact of HPV vaccines: summary of early evidence. J Adolesc Health 2013; 53:679–82; PMID:24263069; http://dx.doi.org/10.1016/j.jadohealth.2013.09.018
   PubMed Web of Science ®Google Scholar
• Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007–2010. Am J Public Health 2012; 102:833–5; PMID:22420808; http://dx.doi.org/10.2105/AJPH.2011.300465
   PubMed Web of Science ®Google Scholar
• Pollock KG, Kavanagh K, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Cruickshank M, Palmer TJ, Nicoll S et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 2014; 111:1824–30; PMID:25180766; http://dx.doi.org/10.1038/bjc.2014.479
   PubMed Web of Science ®Google Scholar
• Baldur-Felskov B, Dehlendorff C, Junge J, Munk C, Kjaer SK. Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control 2014; 25:915–22; PMID:24797870; http://dx.doi.org/10.1007/s10552-014-0392-4
   PubMed Web of Science ®Google Scholar
• Powell SE, Hariri S, Steinau M, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Unger ER, Markowitz LE. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 2012; 31:109–13; PMID:23137842; http://dx.doi.org/10.1016/j.vaccine.2012.10.092
   PubMed Web of Science ®Google Scholar
• Hariri S, Bennett NM, Niccolai LM, Schafer S, Park IU, Bloch KC, Unger ER, Whitney E, Julian P, Scahill MW et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008–2012. Vaccine 2015; 33:1608–13; PMID:25681664; http://dx.doi.org/10.1016/j.vaccine.2015.01.084
   PubMed Web of Science ®Google Scholar
• Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States. Vaccine 2013; 31:3899–905; PMID:23820080; http://dx.doi.org/10.1016/j.vaccine.2013.06.050
   PubMed Web of Science ®Google Scholar
• Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW, Steinau M, Watson M, Wilkinson EJ, Hopenhayn C et al. US assessment of HPV types in cancers: Implications for current and 9-valent HPV Vaccines. J Natl Cancer Inst 2015; 107:djv086; PMID:25925419; http://dx.doi.org/10.1093/jnci/djv086
   PubMedGoogle Scholar
• Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, Bocchini JA, Jr., Unger ER. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63: 1–30; PMID:25167164.
   PubMed Web of Science ®Google Scholar
• Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, Curtis RC, Markowitz L. Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014. MMWR Morb Mortal Wkly Rep 2014; 63:620–4; PMID:25055185
   PubMed Web of Science ®Google Scholar
• Petrosky E, Bocchini JA, Jr., Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015; 64:300–4; PMID:25811679.
   PubMed Web of Science ®Google Scholar
• Hariri S, Unger ER, Schafer S, Niccolai LM, Park IU, Bloch KC, Bennett NM, Steinau M, Johnson ML, Markowitz LE. HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States. Cancer Epidemiol Biomarkers Prev 2015; 24:393–9; PMID:25416715; http://dx.doi.org/10.1158/1055-9965.EPI-14-0649
   PubMed Web of Science ®Google Scholar
• Weiss TW, Pillsbury MT, Dasbach EJ. Potential health and economic impact of the investigational 9-valent HPV vaccine in the United States. 29th International Papillomavirus Conference and Clinical Workshop, Seattle, Washington, August 21-25, 2014.
   Google Scholar
• Brisson M, Laprise J-F, Chesson HW, Drolet M, Malagón T, Boily MC, Markowitz LE. Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States. J Natl Cancer Inst 2015; 108:djv282; PMID:26438574
   PubMedGoogle Scholar
• Markowitz L. Proposed HPV vaccination recommendations. 2015. Presentation to the Advisory Committee on Immunization Practices, Atlanta, Georgia, February 26, 2015.
   Google Scholar
• Brisson M, Bénard E, Drolet M, Baussano I, Berkhof J, Boily MC, Canfell K, Chesson H, Jit M, Vänskä S, et al. Population-level impact, herd immunity and elimination after HPV vaccination: a systematic review and meta-analysis of predictions of 17 transmission dynamic models. Abstract HPV15–0413. 30th International Papillomavirus Conference and Clinical Workshop. September 17-21, 2015. Lisbon, Portugal.
   Google Scholar
• Drolet M, Bénard E, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JM, Cummings T et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15:565-80; PMID:25744474; http://dx.doi.org/10.1016/S1473-3099(14)71073-4
   PubMed Web of Science ®Google Scholar
• Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The estimated impact of human papillomavirus vaccine coverage on the lifetime cervical cancer burden among girls currently aged 12 years and younger in the United States. Sex Transm Dis 2014; 41:656-9; PMID:25299411; http://dx.doi.org/10.1097/OLQ.0000000000000199
   PubMed Web of Science ®Google Scholar
• Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27; PMID:17494925; http://dx.doi.org/10.1056/NEJMoa061741
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43; PMID:17494926; http://dx.doi.org/10.1056/NEJMoa061760
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8; PMID:15863374; http://dx.doi.org/10.1016/S1470-2045(05)70101-7
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED, Jr., Ngan Y, Petersen LK, Lazcano-Ponce E et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372:711-23; PMID:25693011; http://dx.doi.org/10.1056/NEJMoa1405044
   PubMed Web of Science ®Google Scholar
• Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:781-9; PMID:Can't; http://dx.doi.org/10.1016/S1473-3099(12)70187-1
   PubMed Web of Science ®Google Scholar
• Dorell C, Stokley S, Yankey D, Jeyarajah J, MacNeil J, Markowitz L. National and state vaccination coverage among adolescents aged 13 through 17 years–United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:671-7; PMID:22932301.
   PubMedGoogle Scholar
• Elam-Evans LD, Yankey D, Jeyarajah J, Singleton JA, Curtis RC, MacNeil J, Hariri S. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years–United States, 2013. MMWR Morb Mortal Wkly Rep 2014; 63:625-33; PMID:25055186.
   PubMed Web of Science ®Google Scholar
• Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309:1793-802; PMID:23632723; http://dx.doi.org/10.1001/jama.2013.1625
   PubMed Web of Science ®Google Scholar
• Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Behre U et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccin Immunother 2014; 10:1155-65; PMID:24576907; http://dx.doi.org/10.4161/hv.28022
   PubMed Web of Science ®Google Scholar
• Lazcano-Ponce E, Stanley M, Muñoz N, Torres L, Cruz-Valdez A, Salmerón J, Rojas R, Herrero R, Hernández-Ávila M. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose compared with a three-dose schedule at 21 months. Vaccine 2014; 32:725-32; PMID:24355090; http://dx.doi.org/10.1016/j.vaccine.2013.11.059
   PubMed Web of Science ®Google Scholar
• Jit M, Choi YH, Laprise JF, Boily MC, Drolet M, Brisson M. Two-dose strategies for human papillomavirus vaccination: how well do they need to protect? Vaccine 2014; 32:3237-3242; PMID:24726246; http://dx.doi.org/10.1016/j.vaccine.2014.03.098
   PubMed Web of Science ®Google Scholar
• Henk HJ, Insinga RP, Singhal PK, Darkow T. Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population. J Low Genit Tract Dis 2010; 14:29-36; PMID:20040833; http://dx.doi.org/10.1097/LGT.0b013e3181ac05e9
   PubMed Web of Science ®Google Scholar
• Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: A population-based study. Am J Obstet Gynecol 2004; 191:105-13; PMID:15295350; http://dx.doi.org/10.1016/j.ajog.2004.01.043
   PubMed Web of Science ®Google Scholar
• Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 2004; 191:114-20; PMID:15295351; http://dx.doi.org/10.1016/j.ajog.2004.01.042
   PubMed Web of Science ®Google Scholar
• Drolet M, Brisson M, Maunsell E, Franco EL, Coutlee F, Ferenczy A, Fisher W, Mansi JA. The psychosocial impact of an abnormal cervical smear result. Psychooncology 2012; 21:1071-81; PMID:21695747; http://dx.doi.org/10.1002/pon.2003
   PubMed Web of Science ®Google Scholar
• Hoy T, Singhal PK, Willey VJ, Insinga RP. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin 2009; 25:2343-51; PMID:19650749; http://dx.doi.org/10.1185/03007990903136378
   PubMed Web of Science ®Google Scholar
• Chesson HW, Ekwueme DU, Saraiya M, Watson M, Lowy DR, Markowitz LE. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine 2012; 30:6016-9; PMID:22867718; http://dx.doi.org/10.1016/j.vaccine.2012.07.056
   PubMed Web of Science ®Google Scholar
• Drolet M, Brisson M, Maunsell E, Franco EL, Coutlee F, Ferenczy A, Ratnam S, Fisher W, Mansi JA. The impact of anogenital warts on health-related quality of life: a 6-month prospective study. Sex Transm Dis 2011; 38:949-56; PMID:21934571; http://dx.doi.org/10.1097/OLQ.0b013e3182215512
   PubMed Web of Science ®Google Scholar
• Woodhall SC, Jit M, Soldan K, Kinghorn G, Gilson R, Nathan M, Ross JD, Lacey CJ. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sex Transm Infect 2011; 87:458-63; PMID:21636616; http://dx.doi.org/10.1136/sextrans-2011-050073
   PubMed Web of Science ®Google Scholar
• Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011; 343:d5775; PMID:21951758; http://dx.doi.org/10.1136/bmj.d5775
   PubMed Web of Science ®Google Scholar
• Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998; 36:778-92; PMID:9630120; http://dx.doi.org/10.1097/00005650-199806000-00002
   PubMed Web of Science ®Google Scholar
• Armstrong LR, Preston EJ, Reichert M, Phillips DL, Nisenbaum R, Todd NW, Jacobs IN, Inglis AF, Manning SC, Reeves WC. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin Infect Dis 2000; 31:107-9; PMID:10913405; http://dx.doi.org/10.1086/313914
   PubMed Web of Science ®Google Scholar
• Chesson HW, Forhan SE, Gottlieb SL, Markowitz LE. The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine 2008; 26:4513-18; PMID:18598734; http://dx.doi.org/10.1016/j.vaccine.2008.06.045
   PubMed Web of Science ®Google Scholar
• Marsico M, Mehta V, Chastek B, Liaw KL, Derkay C. Estimating the incidence and prevalence of juvenile-onset recurrent respiratory papillomatosis in publicly and privately insured claims databases in the United States. Sex Transm Dis 2014; 41:300-5; PMID:24722383; http://dx.doi.org/10.1097/OLQ.0000000000000115
   PubMed Web of Science ®Google Scholar